Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;8(7):961-70.
doi: 10.4161/hv.21080. Epub 2012 Jul 1.

A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication

Paulo H Verardi  1 , Allison Titong, Caitlin J Hagen
Affiliations
Review

A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication

Paulo H Verardi et al. Hum Vaccin Immunother. 2012 Jul.

Abstract

In 1796, Edward Jenner introduced the concept of vaccination with cowpox virus, an Orthopoxvirus within the family Poxviridae that elicits cross protective immunity against related orthopoxviruses, including smallpox virus (variola virus). Over time, vaccinia virus (VACV) replaced cowpox virus as the smallpox vaccine, and vaccination efforts eventually led to the successful global eradication of smallpox in 1979. VACV has many characteristics that make it an excellent vaccine and that were crucial for the successful eradication of smallpox, including (1) its exceptional thermal stability (a very important but uncommon characteristic in live vaccines), (2) its ability to elicit strong humoral and cell-mediated immune responses, (3) the fact that it is easy to propagate, and (4) that it is not oncogenic, given that VACV replication occurs exclusively within the host cell cytoplasm and there is no evidence that the viral genome integrates into the host genome. Since the eradication of smallpox, VACV has experienced a renaissance of interest as a viral vector for the development of recombinant vaccines, immunotherapies, and oncolytic therapies, as well as the development of next-generation smallpox vaccines. This revival is mainly due to the successful use and extensive characterization of VACV as a vaccine during the smallpox eradication campaign, along with the ability to genetically manipulate its large dsDNA genome while retaining infectivity and immunogenicity, its wide mammalian host range, and its natural tropism for tumor cells that allows its use as an oncolytic vector. This review provides an overview of new uses of VACV that are currently being explored for the development of vaccines, immunotherapeutics, and oncolytic virotherapies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wehrle PF. A reality in our time--certification of the global eradication of smallpox. J Infect Dis. 1980;142:636–8. doi: 10.1093/infdis/142.4.636. - DOI - PubMed
    1. Fenner F, Henderson DA, Arita I, Jeek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988.
    1. Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields' virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2906-45.
    1. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis. 1970;122:303–9. doi: 10.1093/infdis/122.4.303. - DOI - PubMed
    1. Lane JM, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med. 2003;138:488–93. - PubMed

Publication types

LinkOut - more resources